The detection of GPC-1 in urine or blood, perhaps in combination with PSA and/or other biomarkers, may provide clinical benefit in terms of less invasive testing, earlier and more accurate detection of prostate cancer, and decrease the number of unnecessary biopsies. The gene discussed is KLK3; the disease is prostate cancer.